Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy-Reference-Cited by-同舟云学术

Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy

Published:2002-08-10 Issue:12 Volume:13 Page:1505-1514
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Hemminki Akseli¹,Wang Minghui²,Desmond Renee A.³,Strong Theresa V.⁴,Alvarez Ronald D.⁵,Curiel David T.²

Affiliation:

1. Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery and Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35294 and Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35294

2. Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery and Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35294

3. Comprehensive Cancer Center Biostatistics Unit, University of Alabama at Birmingham, Birmingham, AL 35294

4. Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294

5. Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/10430340260185139

Reference30 articles.

1. Adenoviral-Mediated Suicide Gene Therapy for Ovarian Cancer

2. Using a Tropism-Modified Adenoviral Vector to Circumvent Inhibitory Factors in Ascites Fluid

3. Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial;Clinical Cancer Research;2024-03-27

2. M11: A Tropism-Modified Oncolytic Adenovirus Arming with a Tumor-Homing Peptide for Advanced Ovarian Cancer Therapies;Human Gene Therapy;2022-03-01

3. Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies;Cancers;2020-11-11

4. Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer;Cancer Gene Therapy;2020-09-19

5. Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies;Clinical Cancer Research;2018-05-24